<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03159676</url>
  </required_header>
  <id_info>
    <org_study_id>17-000680</org_study_id>
    <secondary_id>ROR1752</secondary_id>
    <nct_id>NCT03159676</nct_id>
  </id_info>
  <brief_title>Proton-Based Stereotactic Ablative Body Radiotherapy for Prostate Cancer</brief_title>
  <official_title>Proton-Based Stereotactic Ablative Body Radiotherapy (SABR) for Select Patients With Clinically Localized Prostate Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stereotactic ablative body radiotherapy (SABR), or stereotactic body radiotherapy (SBRT), is&#xD;
      a specialized form of radiotherapy used to treat prostate cancer with five treatments over&#xD;
      two weeks, compared with a conventional eight-week or longer treatment course. The purpose of&#xD;
      this trial is to investigate the effect that proton-based SABR has on quality-of-life in&#xD;
      patients with localized prostate cancer. The evaluation and treatment will otherwise follow&#xD;
      standard of care, and is not considered investigational.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with low-risk or intermediate-risk, clinically localized prostate cancer will be&#xD;
      evaluated according to standard of care medical practices. The evaluation includes history&#xD;
      and examination, prostate-specific antigen (PSA) blood testing, and review of the prior&#xD;
      prostate biopsy pathology report; radiology scans (for example, computed tomography [CT],&#xD;
      magnetic resonance imaging [MRI], radionuclide bone scan) may be done also; recently&#xD;
      completed testing may not need to be repeated. Small markers will be placed in the prostate&#xD;
      to guide the proton beam stereotactic ablative body radiotherapy (SABR) treatments, and a&#xD;
      hydrogel spacer may also be placed between the prostate and the rectum to push the rectum&#xD;
      away from the prostate; the hydrogel spacer will dissolve a few months later. Participants&#xD;
      will receive five (5) proton SABR treatments over a two (2) week time period. The study will&#xD;
      have participants complete a quality-of life questionnaire and be evaluated for side-effects&#xD;
      before starting SABR, at the end of SABR, at three (3), six (6) and 12 months after SABR, and&#xD;
      then yearly for five (5) years. Evaluation of the cancer status will follow standard of care&#xD;
      practices for at least ten (10) years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 12, 2017</start_date>
  <completion_date type="Anticipated">June 2029</completion_date>
  <primary_completion_date type="Anticipated">June 2029</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of late grade ≥3 Gastrointestinal and Renal and Urinary/Genitourinary adverse events at 24 months after SABR</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical (PSA) failure</measure>
    <time_frame>120 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>60 months</time_frame>
    <description>Patient-reported questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>120 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton beam</intervention_name>
    <description>Proton beam</description>
    <other_name>Radiation therapy</other_name>
    <other_name>Radiotherapy</other_name>
    <other_name>Stereotactic ablative body radiotherapy</other_name>
    <other_name>Stereotactic body radiotherapy</other_name>
    <other_name>SABR</other_name>
    <other_name>SBRT</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult male patients with prostate cancer.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male, age ≥ 18 years.&#xD;
&#xD;
          -  Histological confirmation of adenocarcinoma of prostatic origin.&#xD;
&#xD;
          -  AJCC 7th edition clinical T1b-T2b.&#xD;
&#xD;
          -  AJCC clinical staging rules do not include findings from biopsy or imaging.&#xD;
&#xD;
          -  Gleason score ≤7 (International Society of Urological Pathologists grades 1-3).&#xD;
&#xD;
          -  Serum prostate-specific antigen ≤20 ng/mL.&#xD;
&#xD;
          -  Prostate-specific antigen &lt;10 ng/mL, if dutasteride within last 90 days or finasteride&#xD;
             within last 30 days.&#xD;
&#xD;
          -  Zubrod performance score 0-1.&#xD;
&#xD;
          -  Prostate volume &lt;75-cc, determined by ultrasound, computed tomography or magnetic&#xD;
             resonance imaging (modality with lesser volume is acceptable).&#xD;
&#xD;
          -  If neoadjuvant-concurrent androgen suppression is used, the prostate volume after the&#xD;
             start of androgen suppression may be used.&#xD;
&#xD;
          -  American Urological Association voiding symptom index ≤15.&#xD;
&#xD;
          -  Ability to complete questionnaire(s) by themselves or with assistance.&#xD;
&#xD;
          -  Participation in a patient-reported outcomes survey program, inclusive of the Expanded&#xD;
             Prostate Index Composite and CTCAE instruments.&#xD;
&#xD;
          -  Ability to provide informed written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Radiological- or pathologically-confirmed seminal vesicle invasion, lymph node&#xD;
             involvement, or distant metastatic disease.&#xD;
&#xD;
          -  Radiological- or biopsy-confirmed extraprostatic tumor extension without AJCC 7th&#xD;
             edition clinical T3a classification remain eligible.&#xD;
&#xD;
          -  Prior or anticipated external radiotherapy or brachytherapy, transurethral resection&#xD;
             of the prostate, prostatic cryoablation/focused ultrasound/laser therapy,&#xD;
             prostatectomy, or prostatic enucleation.&#xD;
&#xD;
          -  Prior bilateral orchiectomy, planned long-term (&gt;6 months duration) androgen&#xD;
             suppression or peripheral androgen blockade, or chemotherapy or immunotherapy for&#xD;
             prostate cancer.&#xD;
&#xD;
          -  Prior hemi- or total hip arthroplasty.&#xD;
&#xD;
          -  Diabetes mellitus associated with vascular ulcers or wound healing problems,&#xD;
             ulcerative colitis, connective tissue disorder, or chronic (≥120 days) warfarin use&#xD;
             planned.&#xD;
&#xD;
          -  Co-morbid severe concurrent disease which, in the judgment of the investigator, would&#xD;
             result in life expectancy &lt;5 years.&#xD;
&#xD;
          -  Patients with a left cardiac ventricular assist device are ineligible.&#xD;
&#xD;
          -  Patients with an implanted medical electronic device (e.g., cardiac pacemaker) remain&#xD;
             eligible if device monitoring complies with standard of practice (e.g., Cardiology and&#xD;
             Medical Physics evaluation, function checks and during-treatment monitoring).&#xD;
&#xD;
          -  Immunocompromised due to HIV positive state.&#xD;
&#xD;
          -  Medical or psychiatric conditions that preclude informed decision-making or adherence.&#xD;
&#xD;
          -  Prior registration to an Institutional Review Board-approved therapeutic research&#xD;
             study that includes proton beam therapy or photon-based radiotherapy (e.g.,&#xD;
             randomization to proton beam therapy vs. photon-based radiotherapy).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Thomas Pisansky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mayoclinic.org/departments-centers/proton-beam-therapy-program/sections/clinical-trials/rsc-20185494</url>
    <description>Mayo Clinic Proton Beam Therapy Clinical Trials</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 17, 2017</study_first_submitted>
  <study_first_submitted_qc>May 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2017</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Thomas Pisansky</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>Radiation therapy</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Proton</keyword>
  <keyword>Proton beam</keyword>
  <keyword>Stereotactic ablative body radiotherapy</keyword>
  <keyword>Stereotactic body radiotherapy</keyword>
  <keyword>SABR</keyword>
  <keyword>SBRT</keyword>
  <keyword>Localized</keyword>
  <keyword>Low risk</keyword>
  <keyword>Intermediate risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

